KYNB - Kyntra Bio, Inc. News

Lake Street Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $41

Lake Street analyst Daniel Brims initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Buy rating

Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference

SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the

HC Wainwright & Co. Reiterates Buy on Kyntra Bio, Maintains $43 Price Target

HC Wainwright & Co. analyst Matthew Keller reiterates Kyntra Bio (NASDAQ:KYNB) with a Buy and

Kyntra Bio To Reduce The Maximum Aggregate Payments Under Its Royalty Financing Agreement From $125M

Company reduces the maximum aggregate payments under its royalty financing agreement from $125 milli

Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Oblig

SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the signi

seekingalpha.com

Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript

Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates

Kyntra Bio (KYNB) came out with a quarterly loss of $4.68 per share versus the Zacks Consensus Estim

UPDATE: Kyntra Bio Q2 Adj. EPS $(4.68) Misses $(3.18) Estimate, Sales $(1.474M) Miss $2.007M Estimat

Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(4.68) per share which missed the analyst con

Kyntra Bio Q2 2026 Earnings Call: Complete Transcript

On Thursday, Kyntra Bio (NASDAQ:KYNB) discussed second-quarter financial results during its earnings

Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial

Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy?

Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings b

defenseworld.net

Head-To-Head Comparison: Kyntra Bio (NASDAQ:KYNB) and Pharmaxis (OTCMKTS:PXSLY)

Pharmaxis (OTCMKTS:PXSLY - Get Free Report) and Kyntra Bio (NASDAQ: KYNB - Get Free Report) are both

This Performance Food Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations Fo

Wall Street analysts changed outlook on top names. See analyst rating changes on top stocks. PFGC, S

Oppenheimer Initiates Coverage On Kyntra Bio with Outperform Rating, Announces Price Target of $35

Oppenheimer analyst Jay Olson initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Outperform ra

Kyntra Bio Presents New Data For Roxadustat Showing Improvements In Transfusion Independence Regardl

The presentation at EHA also provides additional details on the subgroup of patients (n=37) who met

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ri

SAN FRANCISCO, June 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced additiona

Rodman & Renshaw Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $30

Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Kyntra Bio (NASDAQ:KYNB) w

seekingalpha.com

Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript

Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates

Kyntra Bio (KYNB) came out with a quarterly loss of $3.74 per share versus the Zacks Consensus Estim

Kyntra Bio Q1 EPS $(3.76) Down From $1.15 YoY, Sales $3.738M Up From $2.739M YoY

Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(3.76) per share. This is a 426.96 percent de

Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update

SAN FRANCISCO, May 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial r

Earnings Scheduled For May 11, 2026

Kyntra Bio to Report First Quarter 2026 Financial Results

SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce first

Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know

Kyntra Bio (KYNB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the

Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference

SAN FRANCISCO, April 08, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the

seekingalpha.com

Kyntra Bio, Inc. (KYNB) Q4 2025 Earnings Call Transcript

Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targe

Earnings Scheduled For March 16, 2026

Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings b

Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasd

What's Going On With Kyntra Bio Stock Tuesday?

Kyntra Bio Inc. (NASDAQ: KYNB), formerly Fibrogen, shares fluctuated in Tuesday's premarket session